Eplerenone vs. Spironolactone for Heart Failure and Resistant Hypertension

Efficacy Comparison

Both eplerenone and spironolactone are mineralocorticoid receptor antagonists (MRAs) that effectively treat heart failure and resistant hypertension, as recommended by the American College of Cardiology and the European Society of Cardiology 1, 2
Both medications are considered preferred agents for treating primary aldosteronism and resistant hypertension, according to the American College of Cardiology and the American Heart Association 2, 3, 4

Spironolactone is associated with significantly higher risk of gynecomastia and impotence compared to eplerenone due to its non-selective binding to progesterone and androgen receptors, as reported by the American College of Cardiology 2, 5, 6
Eplerenone was specifically designed with a 9,11-epoxide group to avoid the hormone-associated side effects of spironolactone, as described in the Progress in Retinal and Eye Research 7

Eplerenone may require twice-daily dosing in some patients for adequate blood pressure control, as recommended by the American College of Cardiology and the American Heart Association 2, 6
Male patients particularly benefit from eplerenone due to minimal risk of gynecomastia and sexual dysfunction, as reported by the Progress in Retinal and Eye Research and the American College of Cardiology 7, 2

Both medications require monitoring of serum potassium levels and renal function, and caution in patients with chronic kidney disease or those taking other potassium-sparing medications, as recommended by the American College of Cardiology and the American Heart Association 2, 5
Both medications should be avoided in pregnancy, as recommended by the American College of Cardiology 8

Eplerenone was specifically engineered with a 9,11-epoxide group to achieve selective binding to mineralocorticoid receptors with minimal affinity for progesterone and androgen receptors 9

In the RALES trial, 10% of patients on spironolactone developed painful gynecomastia 10

Check potassium and creatinine at baseline, then at 2-3 days, 7 days, monthly for 3 months, then every 3 months, and hold therapy if potassium >5.5 mEq/L; discontinue if >6.0 mEq/L, as recommended by the American Heart Association 11
Contraindicated if baseline potassium >5.0 mEq/L or creatinine >2.5 mg/dL in men (>2.0 mg/dL in women) or eGFR <30 mL/min/1.73m², according to the American College of Cardiology 11
Discontinue potassium supplements when initiating either agent, as advised by the American Heart Association 11